Gain Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. (ticker: GANX) is a U.S.-based biotechnology company listed on the Nasdaq Global Market in the United States. For European investors, it fits the profile of a speculative small-cap biotech: the company is focused on drug discovery and development, not on an established commercial franchise. Gain Therapeutics was incorporated in Delaware on June 26, 2020, and completed its IPO in March 2021. Its operating headquarters are in Bethesda, Maryland, placing it in one of the most important biotech corridors in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1819411/000110465926058649/ganx-20260331x10q.htm)) The company’s strategy is built around novel small-molecule therapeutics aimed at diseases across several therapeutic areas, including central nervous system disorders, lysosomal storage disorders, metabolic disorders, and other conditions that may be addressed through protein degradation, including oncology. At present, the core asset is GT-02287, a clinical-stage candidate being developed for Parkinson’s disease with and without GBA1 mutations. Gain Therapeutics says it has assembled a substantial preclinical package supporting the program’s mechanism of action, in vivo pharmacology, and safety profile. In other words, the investment case currently depends heavily on clinical validation of this lead asset and the company’s ability to expand beyond a single main program. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1819411/000110465926058649/ganx-20260331x10q.htm)) From a competitive standpoint, Gain Therapeutics operates in a very crowded neurodegeneration and CNS innovation landscape, where differentiation is driven by scientific novelty, target validation, tolerability, and execution speed. The company does not yet generate product revenue and continues to report operating losses and negative operating cash flow. It has funded itself primarily through equity issuance and capital-markets transactions. As of March 31, 2026, it held $16.5 million in cash and cash equivalents. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1819411/000110465926058649/ganx-20260331x10q.htm)) Recent developments matter for investors. On March 26, 2026, the company reported its full-year 2025 results and provided a business update. It also continued to use its at-the-market equity program with Oppenheimer, under which it sold 184,662 shares in Q1 2026 and an additional 296,697 shares between April 1 and May 8, 2026. That funding pattern underscores the company’s ongoing reliance on external capital and the associated dilution risk. For GANX shareholders, the key catalysts remain clinical updates, additional preclinical validation, and any progress toward regulatory advancement of GT-02287. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1819411/000110465926058649/ganx-20260331x10q.htm))